Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207491 · ClinicalTrials.gov registry record · Phase 3
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 411
- Enrollment target
NCT02207491: Completed Phase 3 study, sponsored by Aerie Pharmaceuticals.
NCT02207491 is a Phase 3 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 411 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207491, a Phase 3 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 411 participants
- Enrollment target
Study Summary
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
Primary Outcome
The primary efficacy outcome is mean IOP
Interventions
- OTHER Placebo
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG Timolol maleate Ophthalmic Solution 0.5% BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
What the finished NCT02207491 record still lists
NCT02207491 is an interventional study that assigns participants to a tested intervention. The registered 411 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02207491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02207491 about?
NCT02207491 is a clinical study titled "Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension". To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
What is the current status of trial NCT02207491?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 411 participants. The study started on 2014-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02207491?
The interventions under investigation include: Placebo (OTHER), AR-13324 Ophthalmic Solution 0.02% (DRUG), Timolol maleate Ophthalmic Solution 0.5% BID (DRUG).
Who is sponsoring clinical trial NCT02207491?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02207491's enrollment target sits among peer trials
411 909th of 2000 higher than 1,092 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia